Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials

M Porta, J W Hainer, S-O Jansson, A Malm, R Bilous, N Chaturvedi, J H Fuller, Roland Blunch Klein, T Orchard, Hans-Henrik Dyring Parving, A-K Sjølie, DIRECT Study Group

    33 Citationer (Scopus)

    Abstract

    The teratogenic consequences of angiotensin-converting enzyme inhibitors angiotensin receptor blockers (ARBs) during the second and third trimesters of pregnancy are well described. However, the consequences of exposure during the first trimester are unclear, especially in diabetes. We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy.
    OriginalsprogEngelsk
    TidsskriftDiabetologia
    Vol/bind54
    Udgave nummer6
    Sider (fra-til)1298-303
    Antal sider6
    ISSN0012-186X
    DOI
    StatusUdgivet - 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials'. Sammen danner de et unikt fingeraftryk.

    Citationsformater